...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Computational modeling and biological validation of novel non-steroidal ligands for the cholesterol recognition/interaction amino acid consensus (CRAC) motif of the mitochondrial translocator protein (TSPO)
【24h】

Computational modeling and biological validation of novel non-steroidal ligands for the cholesterol recognition/interaction amino acid consensus (CRAC) motif of the mitochondrial translocator protein (TSPO)

机译:线粒体转运蛋白(TSPO)的胆固醇识别/相互作用氨基酸共有(CRAC)主题的新型非甾体配体的计算模型和生物学验证

获取原文
获取原文并翻译 | 示例
           

摘要

Mitochondria play a critical role in the physiological homeostasis of the cell, contributing to numerous cellular processes, including bioenergetics, metabolism and cell life and death. Owing to their keystone role, mitochondria have gained much attention as pharmacological targets. The outer mitochondrial integral membrane translocator protein (TSPO) has attracted a significant degree of pharmacological interest owing to its ability to bind a number of classes of drugs with high affinity and specificity. In addition to its well-characterized drug binding site, TSPO possess an additional high-affinity ligand binding site, originally identified for its ability to bind the lipid cholesterol, which was named the cholesterol recognition/interaction amino acid consensus (CRAC) motif. Previous investigations from our laboratory identified additional ligands targeted to TSPO's CRAC motif which are able to potently inhibit mitochondrial cholesterol transport and steroid biosynthesis, processes for which TSPO has been well-characterized. However, all of these compounds possessed the steroidal backbone common to cholesterol and steroid hormones. In our efforts to expand our understanding of TSPO's CRAC motif, we performed studies aimed at identifying non-steroidal ligands for this motif. Molecular modeling and in silico screening of large chemical libraries identified a panel of compounds which were subsequently screened for bioactivity in a number of steroidogenic model systems. These efforts identified a family of non-steroidal CRAC ligands able to potently inhibit steroidogenesis, and at higher concentrations, promote apoptosis. In addition, the best candidate in this family was able to suppress testosterone synthesis when administered to rats, indicating that this novel family of non-steroidal CRAC ligands may serve as prototypes for the development of drugs useful for treatment of diseases of steroid overproduction, such as Cushing's syndrome and steroidogenic cell tumors in humans and animals. (C) 2015 Elsevier Ltd. All rights reserved.
机译:线粒体在细胞的生理动态平衡中起关键作用,有助于许多细胞过程,包括生物能,新陈代谢以及细胞的生与死。线粒体由于其关键作用,已成为药理学靶点,引起了广泛关注。外部线粒体整合膜转运蛋白(TSPO)由于具有以高亲和力和特异性结合多种药物的能力,因此引起了极大的药理学兴趣。除了其特征明确的药物结合位点外,TSPO还具有一个额外的高亲和力配体结合位点,该位点最初是由于其结合脂质胆固醇的能力而被鉴定的,被称为胆固醇识别/相互作用氨基酸共有(CRAC)主题。我们实验室先前的调查发现了针对TSPO CRAC主题的其他配体,它们能够有效抑制线粒体胆固醇的转运和类固醇的生物合成,而TSPO的这些特性已被很好地表征。但是,所有这些化合物都具有胆固醇和类固醇激素共有的类固醇骨架。为了扩大对TSPO CRAC主题的理解,我们进行了旨在识别该主题的非甾体配体的研究。大型化学文库的分子建模和计算机筛选确定了一组化合物,这些化合物随后在许多类固醇生成模型系统中进行了生物活性筛选。这些努力确定了一系列非甾体CRAC配体,它们能够有效抑制甾体生成,并在较高浓度下促进细胞凋亡。另外,该家族中最好的候选物当施用于大鼠时能够抑制睾丸激素的合成,这表明该非甾体CRAC配体的新颖家族可以作为开发用于治疗甾体过度生产疾病的药物的原型,例如人和动物的库欣综合症和类固醇生成细胞瘤。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号